Live Breaking News & Updates on Nonpsychiatric Disease

Fact-Checked
Most antipsychotic medications are tied to weight gain, with changes in weight ranging from mild to significant.
iStock (2)
The U.S. Food and Drug Administration (FDA) announced the approval of a once-daily atypical antipsychotic drug, Lybalvi (olanzapine and samidorphan), to treat adults with schizophrenia and adults with bipolar I disorder.
According to its manufacturer, Alkermes, the combination of olanzapine and samidorphan causes significantly less weight gain than traditional Zyprexa (olanzapine), one of the most widely prescribed antipsychotic drugs for treating schizophrenia and bipolar I disorder.
The weight gain on olanzapine has limited its use in patients, due to reluctance of healthcare providers to prescribe it and as a result of patients discontinuing the medication. This is unfortunate since olanzapine is one of the most effective antipsychotics on the market, says René S. Kahn, MD, PhD, who is a professor and chair of the depart ....

New York , United States , Icahn School Of Medicine At Mount Sinai , Drug Administration , Icahn School , Mount Sinai , Popular Myths , Clinical Psychiatry , American Journal , Keeping Your Relationship Strong After , Common Side Effect , Nonpsychiatric Disease , புதியது யார்க் , ஒன்றுபட்டது மாநிலங்களில் , இக்ஹ்ன் பள்ளி ஆஃப் மருந்து இல் ஏற்ற சினை , இக்ஹ்ன் பள்ளி , ஏற்ற சினை , மருத்துவ மனநல மருத்துவம் , அமெரிக்கன் இதழ் ,